Find information on thousands of medical conditions and prescription drugs.

Clobetasol

Clobetasol Propionate comes in ointment and emollient cream presentations. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It is used to treat illnesses such as psoriasis, where it is used for the treatment of scalp and body psoriasis.

Presentations

  • Clobetasol Propionate Ointment USP 0.05%, supplied in 15 g, 30 g, and 45 g tubes.
  • Temovate & Emollient 0.05%, supplied in 15 g (NDC 0173-0454-01), 30 g (NDC 0173-0454-02) and 60 g (NDC 0173-0454-03) tubes.
  • Clobetasol foam 0.05% (Olux®)

Possible side effects

  • Acneform eruptions
  • Allergic contact dermatitis
  • Burning sensation
  • Cracking and fissuring of the skin
  • Cushing's syndrome
  • Dryness
  • Erythema
  • Folliculitis
  • Hypertrichosis
  • Hypopigmentation
  • Itching
  • Irritation
  • Millaria
  • Numbness of fingers
  • Perioral dermatitis
  • Pruritus
  • Secondary infection
  • Skin atrophy
  • Skin maceration
  • Stinging
  • Striae
  • Telangiectasia

Read more at Wikipedia.org


[List your site here Free!]


Clobetasol ointment: topical steroids urged for lichen sclerosus
From OB/GYN News, 5/1/04 by Norra Macready

WHISTLER, B.C. -- Approximately 10%-15% of all cases of lichen sclerosus occur in children, with girls outnumbering boys 10:1, Dr. Sheryll Vanderhooft said at a clinical dermatology seminar sponsored by Medicis.

The clinical features of lichen sclerosus include hypopigmentation, atrophy, telangiectasias, erosions and fissures, purpura, and scarring. Symptoms include pruritus, vaginal discharge, and pain on urination or defecation severe enough to lead to chronic constipation or avoidance of micturition. However, up to 9% of young female patients are asymptomatic, said Dr. Vanderhooft, director of the pediatric dermatology clinic at the University of Utah, Salt Lake City.

The etiology of pediatric lichen sclerosus is unknown, but there may be an association with autoimmunity and with the class II human leukocyte antigen DQ7, just as there is in adults.

She cited a study of children with vulvar lichen sclerosus in which DQ7 was present in 66% of the patients, compared with 31% of controls. Of the patients with DQ7, 16% were homozygous for it, compared with 5% of the controls. Only 4% of the children with lichen sclerosus had another autoimmune disease, but 56% of their parents or grandparents had other autoimmune conditions, leading the investigators to conclude that patients with early-onset lichen sclerosus are likely to have a family history of autoimmune disease, as well as a stronger than average association with DQ7 (Br. J. Dermatol. 142[3]:481-84, 2000).

Lichen sclerosus responds well to treatment with ultrapotent topical steroids, such as clobetasol ointment, which produces few adverse effects in this patient population. Dr. Vanderhooft recommended the ointment over the cream because it doesn't sting.

She described an 11-year-old patient with significant purpura and hypopigmentation due to lichen sclerosus, which resolved within 3 weeks after the patient started applying clobetasol ointment twice a day.

Good results have also been reported with topical tacrolimus, which could be an alternative to steroid therapy. Combination therapy with topical tacrolimus and pimecrolimus is another option. Treatment with testosterone or other topical hormones is not recommended.

In at least one published report, 50% of girls studied who developed lichen sclerosus as children went into remission at puberty, at an average age of 15 years. The likelihood of resolution is greater if the condition occurs before menarche, although many patients experience no change in disease activity when they start menstruating. Dr. Vanderhooft said.

Squamous cell carcinoma of the vulva has been reported in 5% of older adult women with chronic lichen sclerosus. This form of cancer is extremely rare in younger women, however, and the lifetime risk for women who develop lichen sclerosus as children is unknown. The effect of treatment on squamous cell carcinoma risk in this patient population is also unknown.

BY NORRA MACREADY

Los Angeles Bureau

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Clobetasol
Home Contact Resources Exchange Links ebay